Mitochondrial toxicity is associated with virological response in patients with HIV and hepatitis C virus coinfection treated with ribavirin and highly active antiretroviral therapy

Journal of Infectious Diseases

Volumn 202, Issue 1, 2010, Pages 156-160

  Reiberger, Thomas ^a   Kosi, Lana ^a   Maresch, Judith ^a   Breitenecker, Florian ^b   Anna Payer, Berit ^a   Wrba, Fritz ^a   Rieger, Armin ^b   Gangl, Alfred ^a   Peck Radosavljevic, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Universitatsklinik fur Dermatologie   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

PANCREAS ENZYME; PEGINTERFERON ALPHA; RIBAVIRIN; ALPHA2A INTERFERON; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; LACTATE DEHYDROGENASE; LACTIC ACID; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALPHA2A;

ACIDOSIS; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; FATTY LIVER; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MITOCHONDRIAL TOXICITY; MIXED INFECTION; MULTICENTER STUDY; PANCREATITIS; PRIORITY JOURNAL; SIDE EFFECT; BLOOD; CHEMICALLY INDUCED DISORDER; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG ADMINISTRATION; DRUG COMBINATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; L-LACTATE DEHYDROGENASE; LACTIC ACID; MITOCHONDRIAL DISEASES; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 77953689070     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/653214     Document Type: Article

References (13)

1. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999;30(4):1054-1058. (Pubitemid 29458296)
2. + cell nadirs are at risk for faster fibrosis progression and portal hypertension. J Viral Hepat 2009 (Epub ahead of print).
3. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007;21(9):1073-1089.
4. Dixit NM, Perelson AS. The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell Mol Life Sci 2006;63:832-842. (Pubitemid 43724073)
5. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002; 46(3):716-723. (Pubitemid 34157656)
6. Kohler JJ, Lewis W. A brief overview of mechanisms of mitochondrial toxicity from NRTIs. Environ Mol Mutagen 2007;48:166-172. (Pubitemid 46536084)
7. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995;1(5):417-422.
8. Walker UA, Setzer B, Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 2002; 16(16):2165-2173. (Pubitemid 35387271)
9. Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357(9252): 280-281. (Pubitemid 32120863)
10. Moyle G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 2000; 22(8): 911-936; discussion 898.
11. Bani-Sadr F, Goderel I, Penalba C, et al. Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin. J Viral Hepat 2007; 14(9):639-644. (Pubitemid 47258263)
12. Luft FC. Lactic acidosis update for critical care clinicians. J Am Soc Nephrol 2001; 12(Suppl 17):S15-S19.
13. Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000; 33(1): 106-115. (Pubitemid 30418941)